ସେଲୁମେଟିନିବ

ସେଲୁମେଟିନିବ
Clinical data
Trade names	Koselugo
Synonyms	AZD6244, ARRY-142886
AHFS/Drugs.com	monograph
MedlinePlus	a620030
data	US DailyMed: Selumetinib;
Pregnancy; category	Contraindicated;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Metabolism	liver (probably CYP3A4 and CYP2C19)
Metabolites	N‐desmethyl‐selumetinib (active metabolite)
Elimination half-life	5.3–7.2 hrs
Excretion	mostly via bile
Identifiers
	IUPAC name 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;
ECHA InfoCard	100.169.311
Chemical and physical data
Formula	C17H15BrClFN4O3
Molar mass	୪୫୭.୬୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO;
	InChI InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) ; Key:CYOHGALHFOKKQC-UHFFFAOYSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Selumetinib

ସେଲୁମେଟିନିବ (ଇଂରାଜୀ ଭାଷାରେ Selumetinib ), କୋସେଲୁଗୋ ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ନ୍ୟୁରୋଫାଇବ୍ରୋମାଟୋସିସ ପ୍ରକାର ୧ (NF-1)ରେ ଥିବା ପ୍ଲେକ୍ସିଫର୍ମ ନ୍ୟୁରୋଫାଇବ୍ରୋମା ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ୧ ବର୍ଷରୁ ଅଧିକ ବୟସରେ ବ୍ୟବହୃତ ହୋଇପାରେ ।^[୩] ଏହାକୁ ଦିନକୁ ଦୁଇଥର ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ପେଟ ଯନ୍ତ୍ରଣା, ଥକାପଣ, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, ରାସ, ଜ୍ୱର ଏବଂ ଗଲୁ ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ହୃତ୍‌ପିଣ୍ଡର ପ୍ରଦାହ ବା ମାୟୋକାର୍ଡ଼ାଇଟିସ, ଆଖି ସମସ୍ୟା, ମାଂସପେଶୀ ଭାଙ୍ଗିବା ବା ରାବଡୋମାୟୋଲାଇସିସ ଏବଂ ରକ୍ତସ୍ରାବ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ^[୪] ଏହା ମାଇଟୋଜେନ-ଆକ୍ଟିଭେଟେଡ୍ ପ୍ରୋଟିନ କାଇନେଜ ୧ ଓ ୨କୁ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩]

୨୦୨୦ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୧ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ସେଲୁମେଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଥରକୁ ୨୫ମିଗ୍ରା ମାତ୍ରାରେ ଦିନ‌କୁ ଦୁଇ ଥର ଦେଲେ ଏକ ବର୍ଷର ଚିକିତ୍ସା ନିମନ୍ତେ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୧୫୦,୦୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହେଉଥିଲା ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ Dymond, Angela W.; Howes, Colin; Pattison, Christine; So, Karen; Mariani, Gabriella; Savage, Mark; Mair, Stuart; Ford, Gill; Martin, Paul (2016). "Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects". Clinical Therapeutics. 38 (11): 2447–2458. doi:10.1016/j.clinthera.2016.09.002. PMID 27751676.
↑ ^୨.୦ ^୨.୧ ^୨.୨ Patel, Y. T.; Daryani, V. M.; Patel, P.; Zhou, D.; Fangusaro, J.; Carlile, D. J.; Martin, P. D.; Aarons, L.; Stewart, C. F. (2017). "Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas". CPT: Pharmacometrics & Systems Pharmacology. 6 (5): 305–314. doi:10.1002/psp4.12175. PMC 5445231. PMID 28326681.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Selumetinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 April 2021. Retrieved 12 October 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Koselugo- selumetinib capsule". DailyMed. 10 April 2020. Archived from the original on 18 April 2020. Retrieved 18 April 2020.
↑ "EU/3/18/2050: Orphan designation for the treatment of neurofibromatosis type 1". Archived from the original on 25 June 2019. Retrieved 12 October 2021.
↑ "Koselugo Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 12 October 2021.

[Dymond-1] Dymond, Angela W.; Howes, Colin; Pattison, Christine; So, Karen; Mariani, Gabriella; Savage, Mark; Mair, Stuart; Ford, Gill; Martin, Paul (2016). "Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects". Clinical Therapeutics. 38 (11): 2447–2458. doi:10.1016/j.clinthera.2016.09.002. PMID 27751676.

[Patel-2] ୨.୦ ^୨.୧ ^୨.୨ Patel, Y. T.; Daryani, V. M.; Patel, P.; Zhou, D.; Fangusaro, J.; Carlile, D. J.; Martin, P. D.; Aarons, L.; Stewart, C. F. (2017). "Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas". CPT: Pharmacometrics & Systems Pharmacology. 6 (5): 305–314. doi:10.1002/psp4.12175. PMC 5445231. PMID 28326681.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Selumetinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 April 2021. Retrieved 12 October 2021.

[PI2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Koselugo- selumetinib capsule". DailyMed. 10 April 2020. Archived from the original on 18 April 2020. Retrieved 18 April 2020.

[5] "EU/3/18/2050: Orphan designation for the treatment of neurofibromatosis type 1". Archived from the original on 25 June 2019. Retrieved 12 October 2021.

[6] "Koselugo Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 12 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]